CL2011001493A1 - Uso local de estriol para un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres. - Google Patents

Uso local de estriol para un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.

Info

Publication number
CL2011001493A1
CL2011001493A1 CL2011001493A CL2011001493A CL2011001493A1 CL 2011001493 A1 CL2011001493 A1 CL 2011001493A1 CL 2011001493 A CL2011001493 A CL 2011001493A CL 2011001493 A CL2011001493 A CL 2011001493A CL 2011001493 A1 CL2011001493 A1 CL 2011001493A1
Authority
CL
Chile
Prior art keywords
estriol
women
prevention
treatment
local use
Prior art date
Application number
CL2011001493A
Other languages
English (en)
Inventor
Del Prado Jaime Moscoso
Magro Concepcion Nieto
Fernandez Alvaro Acebron
Lousame Dolores Blanco
Original Assignee
Italfarmaco Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001493(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Sa filed Critical Italfarmaco Sa
Publication of CL2011001493A1 publication Critical patent/CL2011001493A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso local de estriol para la prevención y/o el tratamiento de la atrofia urogenital en mujeres con riesgo de padecer una patología cardio vascular o que ya la padecen.
CL2011001493A 2008-12-19 2011-06-17 Uso local de estriol para un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres. CL2011001493A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200803623A ES2344675B1 (es) 2008-12-19 2008-12-19 Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.

Publications (1)

Publication Number Publication Date
CL2011001493A1 true CL2011001493A1 (es) 2012-01-13

Family

ID=41050933

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001493A CL2011001493A1 (es) 2008-12-19 2011-06-17 Uso local de estriol para un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.

Country Status (24)

Country Link
US (1) US8835414B2 (es)
EP (1) EP2376086B1 (es)
JP (1) JP2012512818A (es)
KR (1) KR101734380B1 (es)
CN (1) CN102325533A (es)
CA (1) CA2747314C (es)
CL (1) CL2011001493A1 (es)
CO (1) CO6382128A2 (es)
CY (1) CY1120971T1 (es)
DK (1) DK2376086T3 (es)
EC (1) ECSP11011211A (es)
ES (2) ES2344675B1 (es)
HR (1) HRP20182022T1 (es)
HU (1) HUE040394T2 (es)
LT (1) LT2376086T (es)
MA (1) MA32984B1 (es)
MX (1) MX2011006696A (es)
PE (1) PE20120496A1 (es)
PL (1) PL2376086T3 (es)
PT (1) PT2376086T (es)
RU (1) RU2555752C2 (es)
SI (1) SI2376086T1 (es)
SM (1) SMT201800648T1 (es)
WO (1) WO2010069621A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016110839A1 (en) * 2015-01-05 2016-07-14 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Nanoparticles and methods for preparation thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1866M (fr) 1961-04-07 1963-06-17 Vismara Francesco Spa Nouveaux éthers des hormones oestrogenes.
AU565354B2 (en) 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
FI913127A0 (fi) 1989-10-31 1991-06-27 Watson Lab Vid slemhinnan haeftade stoedsystem foer frigoerande av ett terapeutiskt aemne.
ATE113841T1 (de) 1989-10-31 1994-11-15 Columbia Lab Inc Mittel zur feuchthaltung vaginalen gewebes.
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
IT1275816B1 (it) 1995-10-27 1997-10-17 Montefarmaco Spa Composizioni farmaceutiche solide per uso vaginale
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
ATE442844T1 (de) 1996-11-14 2009-10-15 Lipomedica Ehf Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
CA2366688A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
CA2386422A1 (en) 1999-10-22 2001-04-26 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
ATE442147T1 (de) * 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
ATE355854T1 (de) 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
JP3655846B2 (ja) 2001-06-27 2005-06-02 埼玉日本電気株式会社 Ｃｄｍａ移動通信システム、及びその呼切断防止方法
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
CA2617106A1 (en) 2005-08-12 2007-02-22 Drugtech Corporation Estrogen compositions and therapeutic methods of use thereof
CA2578790A1 (en) 2005-12-16 2007-06-16 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
CA2637608A1 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008089405A1 (en) 2007-01-19 2008-07-24 Neurosci, Inc. Composition of multiple hormones delivered vaginally in a single cream
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.

Also Published As

Publication number Publication date
HRP20182022T1 (hr) 2019-01-25
RU2011127702A (ru) 2013-01-27
SI2376086T1 (sl) 2019-02-28
KR20110108358A (ko) 2011-10-05
HUE040394T2 (hu) 2019-03-28
CY1120971T1 (el) 2019-12-11
MX2011006696A (es) 2011-07-28
EP2376086A1 (en) 2011-10-19
PL2376086T3 (pl) 2019-05-31
MA32984B1 (fr) 2012-01-02
KR101734380B1 (ko) 2017-05-11
ES2344675B1 (es) 2011-04-28
CA2747314C (en) 2017-04-18
SMT201800648T1 (it) 2019-01-11
DK2376086T3 (en) 2018-12-10
RU2555752C2 (ru) 2015-07-10
WO2010069621A8 (en) 2011-07-21
PT2376086T (pt) 2018-12-18
LT2376086T (lt) 2019-01-10
PE20120496A1 (es) 2012-05-04
CN102325533A (zh) 2012-01-18
CA2747314A1 (en) 2010-06-24
US20110312929A1 (en) 2011-12-22
ES2344675A1 (es) 2010-09-02
ECSP11011211A (es) 2011-08-31
ES2707873T3 (es) 2019-04-05
WO2010069621A1 (en) 2010-06-24
EP2376086B1 (en) 2018-09-19
US8835414B2 (en) 2014-09-16
JP2012512818A (ja) 2012-06-07
CO6382128A2 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
EP1824442A4 (en) PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FROM THE GARCINIA MANGOSTANA L PLANT
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
GT200800098A (es) Anticuerpos anti mn y metodos para su utilización
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2013003577A1 (es) Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI0716985A2 (pt) Composição nutricional, uso da mesma, e, suplemento nutricional para o tratamento de pacientes que sofrem de alergias a alimentos
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
EA200970885A1 (ru) Комбинирование лечения рака с применением il-18 человека и антитела против cd20
AU321236S (en) Waste disposal device
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
ECSP077423A (es) Coadministración de tigeciclina y digoxin
ECSP10010661A (es) Dronedarona para la prevención de la cardioversión
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
ECSP12011893A (es) Combinación de fármacos con teobromina y su uso en terapia
CL2011001493A1 (es) Uso local de estriol para un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.
CL2011003248A1 (es) Composicion farmaceutica que comprende crf y un inhibidor de angiogenesis; util para la prevencion y el tratamiento del cancer.